Bioventus (NASDAQ:BVS) Upgraded to “Strong-Buy” at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Bioventus (NASDAQ:BVS) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

A number of other brokerages have also issued reports on BVS. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Barrington Research raised Bioventus to a “strong-buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Bioventus has a consensus rating of “Buy”.

Bioventus Price Performance

NASDAQ:BVS traded up $0.76 during trading hours on Wednesday, hitting $9.23. 564,957 shares of the stock traded hands, compared to its average volume of 266,570. The company has a quick ratio of 1.14, a current ratio of 1.74 and a debt-to-equity ratio of 1.50. Bioventus has a 1 year low of $5.81 and a 1 year high of $11.25. The company has a market cap of $763.90 million, a price-to-earnings ratio of 76.92 and a beta of 0.78. The stock has a 50 day moving average price of $8.07 and a 200 day moving average price of $7.48.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter. The firm had revenue of $157.90 million during the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.